Cyclacel Pharma (CYCC) Misses Q4 EPS by 12c

Cyclacel Pharma (NASDAQ: CYCC) reported Q4 EPS of ($0.60), $0.12 worse than the analyst estimate of ($0.48).

For earnings history and earnings-related data on Cyclacel Pharma (CYCC) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• United Community Banks sells equipment finance unit for $1.9 billion
• UBS Reiterates Neutral Rating on Clorox (CLX) as External Challenges Persist